These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 18181119)

  • 1. Zinc-binding groups modulate selective inhibition of MMPs.
    Agrawal A; Romero-Perez D; Jacobsen JA; Villarreal FJ; Cohen SM
    ChemMedChem; 2008 May; 3(5):812-20. PubMed ID: 18181119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of hydroxypyrone- and hydroxythiopyrone-based matrix metalloproteinase inhibitors: developing a structure-activity relationship.
    Yan YL; Miller MT; Cao Y; Cohen SM
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1970-6. PubMed ID: 19261472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A bioinorganic perspective on matrix metalloproteinase inhibition.
    Puerta DT; Cohen SM
    Curr Top Med Chem; 2004; 4(15):1551-73. PubMed ID: 15579096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigating chelating sulfonamides and their use in metalloproteinase inhibitors.
    Tanakit A; Rouffet M; Martin DP; Cohen SM
    Dalton Trans; 2012 Jun; 41(21):6507-15. PubMed ID: 22411188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carbamoylphosphonate-based matrix metalloproteinase inhibitor metal complexes: solution studies and stability constants. Towards a zinc-selective binding group.
    Farkas E; Katz Y; Bhusare S; Reich R; Röschenthaler GV; Königsmann M; Breuer E
    J Biol Inorg Chem; 2004 Apr; 9(3):307-15. PubMed ID: 14762707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New beginnings for matrix metalloproteinase inhibitors: identification of high-affinity zinc-binding groups.
    Puerta DT; Lewis JA; Cohen SM
    J Am Chem Soc; 2004 Jul; 126(27):8388-9. PubMed ID: 15237990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs).
    Zhang YM; Fan X; Yang SM; Scannevin RH; Burke SL; Rhodes KJ; Jackson PF
    Bioorg Med Chem Lett; 2008 Jan; 18(1):405-8. PubMed ID: 17980583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix metalloproteinase inhibitors: new challenges in the era of post broad-spectrum inhibitors.
    Nuti E; Tuccinardi T; Rossello A
    Curr Pharm Des; 2007; 13(20):2087-100. PubMed ID: 17627541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and evaluation of novel oxazoline MMP inhibitors.
    Cook GR; Manivannan E; Underdahl T; Lukacova V; Zhang Y; Balaz S
    Bioorg Med Chem Lett; 2004 Oct; 14(19):4935-9. PubMed ID: 15341955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new role for old ligands: discerning chelators for zinc metalloproteinases.
    Jacobsen FE; Lewis JA; Cohen SM
    J Am Chem Soc; 2006 Mar; 128(10):3156-7. PubMed ID: 16522091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of novel semiselective matrix metalloproteinase inhibitors on ex vivo cardiac structure-function.
    Romero-Perez D; Agrawal A; Jacobsen J; Yan Y; Thomas R; Cohen S; Villarreal F
    J Cardiovasc Pharmacol; 2009 Jun; 53(6):452-61. PubMed ID: 19365278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protease inhibitors: synthesis of matrix metalloproteinase and bacterial collagenase inhibitors incorporating 5-amino-2-mercapto-1,3,4-thiadiazole zinc binding functions.
    Scozzafava A; Supuran CT
    Bioorg Med Chem Lett; 2002 Oct; 12(19):2667-72. PubMed ID: 12217351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.
    Tauro M; Laghezza A; Loiodice F; Agamennone M; Campestre C; Tortorella P
    Bioorg Med Chem; 2013 Nov; 21(21):6456-65. PubMed ID: 24071448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Junctophilin-2 is a target of matrix metalloproteinase-2 in myocardial ischemia-reperfusion injury.
    Chan BYH; Roczkowsky A; Cho WJ; Poirier M; Lee TYT; Mahmud Z; Schulz R
    Basic Res Cardiol; 2019 Sep; 114(6):42. PubMed ID: 31506724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zinc-Metalloproteinase Inhibitors: Evaluation of the Complex Role Played by the Zinc-Binding Group on Potency and Selectivity.
    Rouanet-Mehouas C; Czarny B; Beau F; Cassar-Lajeunesse E; Stura EA; Dive V; Devel L
    J Med Chem; 2017 Jan; 60(1):403-414. PubMed ID: 27996256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Matrix metalloproteinase inhibitors: a review on pharmacophore mapping and (Q)SARs results.
    Kontogiorgis CA; Papaioannou P; Hadjipavlou-Litina DJ
    Curr Med Chem; 2005; 12(3):339-55. PubMed ID: 15723623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. To bind zinc or not to bind zinc: an examination of innovative approaches to improved metalloproteinase inhibition.
    Jacobsen JA; Major Jourden JL; Miller MT; Cohen SM
    Biochim Biophys Acta; 2010 Jan; 1803(1):72-94. PubMed ID: 19712708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzymatic activation of a matrix metalloproteinase inhibitor.
    Major Jourden JL; Cohen SM
    Chem Commun (Camb); 2010 Feb; 46(8):1241-3. PubMed ID: 20449263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quest for selectivity in inhibition of matrix metalloproteinases.
    Brown S; Meroueh SO; Fridman R; Mobashery S
    Curr Top Med Chem; 2004; 4(12):1227-38. PubMed ID: 15320723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of sulfonamide group in matrix metalloproteinase inhibitors.
    Cheng XC; Wang Q; Fang H; Xu WF
    Curr Med Chem; 2008; 15(4):368-73. PubMed ID: 18288991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.